Bone Biologics Corp (BBLG): Price and Financial Metrics


Bone Biologics Corp (BBLG): $0.29

-0.01 (-4.63%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

BBLG Stock Price Chart Interactive Chart >

Price chart for BBLG

BBLG Price/Volume Stats

Current price $0.29 52-week high $6.78
Prev. close $0.30 52-week low $0.25
Day low $0.27 Volume 11,625
Day high $0.29 Avg. volume 491,522
50-day MA $0.56 Dividend yield N/A
200-day MA $1.43 Market Cap 2.96M

Bone Biologics Corp (BBLG) Company Bio


Bone Biologics Corporation, a medical device company, focuses on bone regeneration in spinal fusion using the recombinant human protein. Its NELL-1/DBX is a combination product, which is an osteostimulative recombinant protein that provides target specific control over bone regeneration. The company is developing NELL-1/DBX Fusion Device for spinal fusion procedures in skeletally mature patients with degenerative disc disease at one level from L4-S1. Its platform technology has application in delivering enhanced outcomes in the surgical specialties of spinal, orthopedic, general orthopedic, plastic reconstruction, neurosurgery, interventional radiology, and sports medicine. The company has a license agreement with the UCLA Technology Development Group to develop and commercialize NELL-1 for spinal fusion applications. Bone Biologics Corporation was founded in 2004 and is headquartered in Burlington, Massachusetts.


BBLG Latest News Stream


Event/Time News Detail
Loading, please wait...

BBLG Latest Social Stream


Loading social stream, please wait...

View Full BBLG Social Stream

Latest BBLG News From Around the Web

Below are the latest news stories about BONE BIOLOGICS CORP that investors may wish to consider to help them evaluate BBLG as an investment opportunity.

BBLG: A Potential Game-Changer for Back Surgeries

By Brad Sorensen, CFA NASDAQ:BBLG READ THE FULL BBLG RESEARCH REPORT Bone Biologics (NASDAQ:BBLG) is a medical device company focused on addressing the spinal fusion market with their worldwide exclusive use of the NELL-1 technology developed by the UCLA Technology Development Group (UCLA TDG). NELL-1 has shown in clinical studies involving rats the ability to stimulate bone growth in a more

Yahoo | November 15, 2022

Bone Biologics CEO Issues Letter to Stockholders

BURLINGTON, Mass., October 25, 2022--Bone Biologics Corporation (NASDAQ: BBLG), a developer of orthobiologic products for spine fusion markets, today issued the following letter to stockholders from its President and Chief Executive Officer, Jeffrey Frelick.

Yahoo | October 25, 2022

Analysts’ Opinions Are Mixed on These Healthcare Stocks: Argenx Se (ARGX), Roche Holding AG (OtherRHHVF) and Bone Biologics (BBLG)

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Argenx Se (ARGX – Research Report), Roche Holding AG (RHHVF – Research Report) and Bone Biologics (BBLG – Research Report). Argenx Se (ARGX) Wells Fargo analyst Derek Archila maintained a Buy rating on Argenx Se today and set a price target of $469.00. The company's shares closed last Monday at $361.05. According to TipRanks.

Brian Anderson on TipRanks | October 18, 2022

WallachBeth Capital Announces Closing of Bone Biologics $5,100,000 Underwritten Public Offering

WallachBeth Capital LLC, a leading provider of capital markets and institutional execution services announced yesterday the closing of Bone Biologics (NASDAQ: BBLG) previously announced underwritten public offering of units of securities for total gross proceeds of $5,100,000, before deducting underwriting discounts and commissions and other estimated offering expenses.

Yahoo | October 13, 2022

Bone Biologics Announces Closing of $5,100,000 Underwritten Public Offering

BURLINGTON, Mass., October 12, 2022--Bone Biologics Corporation (NASDAQ: BBLG), a developer of orthobiologic products for spine fusion markets, today announced the closing of its previously announced underwritten public offering of units of securities for total gross proceeds of $5,100,000, before deducting underwriting discounts and commissions and other estimated offering expenses. The Company plans to use the net proceeds to fund its planned clinical trials, maintain and extend its patent por

Yahoo | October 12, 2022

Read More 'BBLG' Stories Here

BBLG Price Returns

1-mo -27.50%
3-mo -76.61%
6-mo -81.53%
1-year -92.43%
3-year N/A
5-year N/A
YTD -91.76%
2021 N/A
2020 0.00%
2019 N/A
2018 N/A
2017 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.524 seconds.